|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Characterizing rare and low-frequency height-associated variants in the Japanese population.
|
31562340 |
2019 |
|
Alopecia
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic prediction of male pattern baldness.
|
28196072 |
2017 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Overexpressed PLAGL2 transcriptionally activates Wnt6 and promotes cancer development in colorectal cancer.
|
30535429 |
2019 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
<b>Objective</b>: As a member of the Wnt family, WNT6 contributes to tumorigenesis and the development of various types of cancer.
|
31258769 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
<b>Objective</b>: As a member of the Wnt family, WNT6 contributes to tumorigenesis and the development of various types of cancer.
|
31258769 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Overexpressed PLAGL2 transcriptionally activates Wnt6 and promotes cancer development in colorectal cancer.
|
30535429 |
2019 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Furthermore, WNT6 upregulation showed positive correlation with patients' age (P < .001), tumor grade (P < .001) and distant metastasis (P = .001).
|
30431574 |
2018 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
<b>Conclusion:</b> Our findings establish WNT6 as a novel oncogene in GBM, opening opportunities to develop more rational therapies to treat this highly aggressive tumor.
|
30279739 |
2018 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
The most significant impact of exposure to (S)-NNN was alteration of genes involved in immune regulation (Aire, Ctla4, and CD80), inflammation (Ephx2 and Inpp5d) and cancer (Cdkn2a, Dhh, Fetub B, Inpp5d, Ly6E, Nr1d1, and Wnt6).
|
26785143 |
2016 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
The most significant impact of exposure to (S)-NNN was alteration of genes involved in immune regulation (Aire, Ctla4, and CD80), inflammation (Ephx2 and Inpp5d) and cancer (Cdkn2a, Dhh, Fetub B, Inpp5d, Ly6E, Nr1d1, and Wnt6).
|
26785143 |
2016 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
In GC patients, WNT6 expression was positively associated with the tumor stage and the nodal status, and inversely correlated with the response to ECF (Epi, cisplatin, 5-fluorouracil) chemotherapy.
|
22370641 |
2013 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
<b>Objective</b>: As a member of the Wnt family, WNT6 contributes to tumorigenesis and the development of various types of cancer.
|
31258769 |
2019 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Wnt6 is a member of the Wnt family and may promote tumorigenesis in gastrointestinal cancer and cervical cancer.
|
29963191 |
2018 |
|
Childhood Osteosarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
WNT6 might be a diagnostic marker for osteosarcoma with an AUC of 0.854 combining a specificity of 88.4% and a sensitivity of 77.8%.
|
30431574 |
2018 |
|
Childhood Osteosarcoma
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
Correlation study of DNA methylation of WNT6 gene with osteosarcoma in children.
|
28693164 |
2017 |
|
Malignant neoplasm of stomach
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Epi increased both WNT6/Wnt6 and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg).
|
22370641 |
2013 |
|
Stomach Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Epi increased both WNT6/Wnt6 and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg).
|
22370641 |
2013 |
|
Malignant neoplasm of stomach
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated expression of WNT10A and WNT6 in gastric cancer.
|
11494032 |
2001 |
|
Stomach Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated expression of WNT10A and WNT6 in gastric cancer.
|
11494032 |
2001 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
Secreted Wnt6 mediates diabetes-associated centrosome amplification via its receptor FZD4.
|
31618077 |
2020 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
Secreted Wnt6 mediates diabetes-associated centrosome amplification via its receptor FZD4.
|
31618077 |
2020 |
|
Colorectal Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
These results indicated that PLAGL2 was overexpressed in CRC as a proto‑oncogene and that it could active the Wnt/β‑catenin pathway as a transcription factor by binding with the promoter region of Wnt6.
|
30535429 |
2019 |
|
Secondary malignant neoplasm of liver
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we evaluated the association of WNT6 expression with survival outcomes in CRLM patients undergoing liver resection.
|
31258769 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overexpressed PLAGL2 transcriptionally activates Wnt6 and promotes cancer development in colorectal cancer.
|
30535429 |
2019 |